By Adriano Marchese
Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the drug.
Shares fell 16% to $10.54.
The clinical-stage biopharmaceutical company said the decision was made after it observed pericardial effusion in patients, an adverse effect in which excess fluid builds up around the heart.
The company voluntarily halted all dosing in the phase 2 Tropos trial for the drug cibotercept, which aims to treat pulmonary arterial hypertension.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 15, 2025 09:54 ET (14:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。